Beijing Health Guard Biotech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nonavalent HPV vaccine / Beijing Health Guard Biotech, R-Pharm
NCT05668572: A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Active, not recruiting
3
12000
RoW
Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
Beijing Health Guard Biotechnology, Inc
Human Papillomavirus Infection
07/22
02/23
NCT05662020: A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Active, not recruiting
3
2750
RoW
Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
Beijing Health Guard Biotechnology, Inc, Yunnan Center for Disease Control and Prevention, Mile City Center for Disease Control and Prevention, Qiubei County Center for Disease Control and Prevention, Yanshan County Center for Disease Control and Prevention, National Institutes for Food and Drug Control, China, Shanghai Stem Pharmaceutical Development Co., Ltd.
Human Papillomavirus Infection
11/22
03/28
KLWS-V502-05, NCT06207175: A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Active, not recruiting
3
1260
RoW
Nonavalent HPV study vaccine, Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
Beijing Health Guard Biotechnology, Inc, University of Muhammadiyah Malang Hospital, Dr. M Djamil Hospital, Padang
Human Papillomavirus Infection
11/24
01/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nonavalent HPV vaccine / Beijing Health Guard Biotech, R-Pharm
NCT05668572: A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Active, not recruiting
3
12000
RoW
Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
Beijing Health Guard Biotechnology, Inc
Human Papillomavirus Infection
07/22
02/23
NCT05662020: A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Active, not recruiting
3
2750
RoW
Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
Beijing Health Guard Biotechnology, Inc, Yunnan Center for Disease Control and Prevention, Mile City Center for Disease Control and Prevention, Qiubei County Center for Disease Control and Prevention, Yanshan County Center for Disease Control and Prevention, National Institutes for Food and Drug Control, China, Shanghai Stem Pharmaceutical Development Co., Ltd.
Human Papillomavirus Infection
11/22
03/28
KLWS-V502-05, NCT06207175: A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Active, not recruiting
3
1260
RoW
Nonavalent HPV study vaccine, Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
Beijing Health Guard Biotechnology, Inc, University of Muhammadiyah Malang Hospital, Dr. M Djamil Hospital, Padang
Human Papillomavirus Infection
11/24
01/26

Download Options